What is Nodexus?
Nodexus is at the forefront of developing innovative cell sorting and dispensing technologies, offering a suite of products including the NX One, NX One MAX, and NX One PRO. These systems are engineered for precision and ease of use, catering to a diverse clientele ranging from academic research institutions to commercial biotechnology firms. The company's commitment to gentle sorting techniques ensures high cell viability, a critical factor for applications such as single-cell genomics and CRISPR workflows. By making advanced cellular analysis more accessible and affordable, Nodexus is poised to accelerate research and development in cellular biology.
How much funding has Nodexus raised?
Nodexus has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2021): $30M with participation from RA Capital Management and Section 32
Key Investors in Nodexus
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Section 32
Section 32 (S32) is a venture capital firm that focuses on investing in cutting-edge technology. Founded by Bill Maris, the firm is backed by a team with extensive experience in building iconic companies. Their investment strategy targets innovative startups and emerging technologies.
What's next for Nodexus?
The recent major strategic investment in Nodexus signals a pivotal moment for the company, likely enabling accelerated product development, market expansion, and enhanced R&D capabilities. This infusion of capital, coupled with the company's established expertise in cell sorting technology, positions Nodexus for significant growth. Future endeavors may include scaling production, forging new strategic partnerships, and further refining their product offerings to meet the evolving demands of the genomics and biotechnology industries. The company's focus on affordability and user-friendliness suggests a strategy aimed at broad market penetration and establishing a dominant presence in the cell analysis instrumentation market.
See full Nodexus company page
